Numerous firms reported preliminary revenues along with other business updates on Sunday and Monday ahead of the annual JP Morgan Healthcare Conference.

Following OraSure's November 2024 lawsuit accusing NowDx of misappropriating trade secrets, NowDx has countersued OraSure over similar allegations.

The company received conditional approval from New York State for its new systemic lupus erythematosus and rheumatoid arthritis biomarker assays.

The rapid spinning disk-based immunoassay technology will enhance BioMérieux's offering at the point of care, the firm said.

Last week, readers were most interested in a story about the progress made by test developers toward commercializing rapid tests for sepsis.

The chemiluminescence-based immunoassay is used for the direct quantitative measurement of free testosterone in serum or plasma, with results in 48 minutes.

Biomy has developed its DeepPathFinder digital pathology platform to analyze images to classify cell and tissue types in specific regions.

The NCI-led Vanguard study has selected tests from Guardant Health and ClearNote Health to move forward after a vigorous technology assessment. The company recently published data demonstrating its ...

Innovaccer on Thursday announced separately that it has closed a $275 million Series F funding round that includes participation from Danaher Ventures and others.

Rounding out the other four largest financing rounds in 2024 are proteomics company Alamar Biosciences' $128 million Series C ...